-
In this issue: ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
In this double-blind protocol, normal-weight (body mass index [BMI] 19.0-24.9 kg/m2) and obese (BMI 30.0-39.9 kg/m2) women with regular periods and normal ovarian ultrasound took one of two types of oral contraceptives (OCPs): either 21-day monophasic pills with 20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel.
-
This case-driven discussion of microscopic hematuria includes important guidelines, definitions, and reminders to aid the clinician in managing this common finding.
-
-
Two independent case-control studies investigating the risk of venous thromboembolism (VTE) in users of oral contraceptives (OC) containing 30 mcg of ethinyl estradiol and a progestin component of either drospirenone or levonorgestrel found that VTE risk was two to three times higher in those using a drospirenone pill.
-
The concept that "term" pregnancy applies to any pregnancy extending past 36 completed weeks has been recently strongly challenged.
-
There are at least six different commonly used chemotherapeutic regimens in practice to treat patients with low-risk gestational trophoblastic neoplasia (GTN) with no consensus or previous formal evaluation as to which may be best.
-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
Baseline and 6-month data were collected on morbidly obese women who planned to undergo weight reduction surgery.
-
Dealing with a question about certain dietary items in pregnancy sometimes is daunting because often there is no consensus regarding a proper answer.
